An Outcomes Review of Minimally Invasive Transurethral Convective Water Vapor Energy (WAVE) Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Verhamme KMC et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the triumph project. Eur Urol. 2002;42(4):323–8. Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol. 2008;10(1):14–25. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173(4):1256–61. Hollingsworth JM, Wilt TJ. Lower urinary tract symptoms in men. Br Med J. 2014;349:g4474. doi:10.1136/bmj.g4474. Rosen R et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637–49. Rom M et al. Lower urinary tract symptoms and depression. BJU Int. 2012;110(11c):E918–21. Speakman M et al. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)—focus on the UK. BJU Int. 2015;115(4):508–19. Bautista OM et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials. 2003;24(2):224–43. Kaplan SA, Lee JY, Meehan AG et al. Time course of incident adverse experiences associated with doxazosin, finasteride, and combination therapy in men with benign prostatic hyperplasia: the medical therapy of prostatic symptoms (MTOPS) trial. J Urol. 2015. doi:10.1016/j.juro.2015.11.065. McConnell JD et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98. Verhamme KMC et al. Treatment strategies, patterns of drug use and treatment discontinuation in men with luts suggestive of benign prostatic hyperplasia: the triumph project. Eur Urol. 2003;44(5):539–45. Rassweiler J et al. Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol. 2006;50(5):969–80. Reich O et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246–9. Tang Y et al. Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis. J Endourol. 2014;28(9):1107–14. McVary KT, et al. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). American Urological Association Education and Research, Inc.; 2010. (https://www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm). Barry MJ et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care. 1995;33(4):AS145–55. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7 Suppl 9:S3–14. Rosen RC, Cappelleri JC, Gendrano N. The international index of erectile function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14(4):226–44. Rosen RC et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 2000;11(6):319–26. Rosen RC et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30. Dixon CM et al. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm(®) system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol. 2015;7:13–8. This article is important because it was the first study to establish the acute ablative capabilities using the Rezūm® system in the treatment of benign prostatic hyperplasia. It provides the histologic and MRI evidence of the necrosis of the ablated lesions. Mynderse LA et al. Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology. 2015;86(1):122–7. This research is important because it was the first study to evaluate by MRI the physical effects, through 6 months, of convective thermal energy transfer with water vapor as a means of treating lower urinary tract symptoms due to benign prostatic hyperplasia. Dixon CM, Cedano ER, Pacik D et al. Efficacy and safety of Rezum system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urol. 2015;86:1042–47. This paper is very important because it examines the safety and efficacy of the Rezūm® System over a 12-month follow-up period. It provides data from a series of pilot studies performed at multiple institutions in three countries which demonstrates the treatment efficacy and positive safety profile for this new method of treating LUTS secondary to BPH. McVary KT, Gange, SN, Gittelman MC et al. Minimally invasive prostate convective water vapor energy (WAVE) ablation: A multicenter, randomized, controlled study for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2015. doi:10.1016/j.juro.2015.10.181. This paper is very important because it is the first multicenter, randomized controlled study among 197 patients randomized to convective water vapor energy (WAVE) ablation or control and followed over 12 months. It demonstrates treatment efficacy across multiple treatment end points as well as its safety profile.